|
|
Article: Atlantic Technology Ventures, Inc.'s CT-3 Shows Promising Animal Results for Treatment of Multiple Sclerosis.
- Article from:
- Business Wire
- Article date:
- September 11, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business & Health Editors
NEW YORK--(BW HealthWire)--Sept. 11, 2001
Atlantic Technology Ventures, Inc.'s (OTC: ATLC.OB) proprietary lead compound CT-3 has shown anti-spastic activity in an animal model of multiple sclerosis at a dose level achievable in humans.
CT-3, also identified as Ajulemic Acid, is a non-psychoactive synthetic derivative of a metabolite of tertrahydrocannabinol (THC) shown to have potent anti-inflammatory and analgesic effects. The study was conducted by Professor Dr. David Baker of the Institute of Neurology, University College London, UK.
Spasticity is a common, painful sign that develops during multiple ...
Related newspaper, magazine, and journal articles:
|
|
Article: Atlantic Technology Ventures, Inc. Intends ...
Business Wire;
June 21, 2001 ;
700+ words
... ... BUSINESS WIRE)--June 21, 2001 Atlantic Technology Ventures, Inc. (Nasdaq: ATLC) announced ... quotations and share volume. About Atlantic Technology Ventures, Inc. Atlantic Technology Ventures, Inc. is a publicly held venture ...
|
|